Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,856 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.
Clausen J, Wolf D, Petzer AL, Gunsilius E, Schumacher P, Kircher B, Gastl G, Nachbaur D. Clausen J, et al. Among authors: wolf d. Clin Exp Immunol. 2007 Jun;148(3):520-8. doi: 10.1111/j.1365-2249.2007.03360.x. Clin Exp Immunol. 2007. PMID: 17493020 Free PMC article.
The kinase inhibitor imatinib--an immunosuppressive drug?
Wolf D, Tilg H, Rumpold H, Gastl G, Wolf AM. Wolf D, et al. Among authors: wolf am. Curr Cancer Drug Targets. 2007 May;7(3):251-8. doi: 10.2174/156800907780618293. Curr Cancer Drug Targets. 2007. PMID: 17504122 Review.
The role of missing killer cell immunoglobulin-like receptor ligands in T cell replete peripheral blood stem cell transplantation from HLA-identical siblings.
Clausen J, Kircher B, Auberger J, Schumacher P, Ulmer H, Hetzenauer G, Wolf D, Gastl G, Nachbaur D. Clausen J, et al. Among authors: wolf d. Biol Blood Marrow Transplant. 2010 Feb;16(2):273-80. doi: 10.1016/j.bbmt.2009.10.021. Epub 2009 Oct 24. Biol Blood Marrow Transplant. 2010. PMID: 19857587 Free article.
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Petzer AL, Wolf D, Fong D, Lion T, Dyagil I, Masliak Z, Bogdanovic A, Griskevicius L, Lejniece S, Goranov S, Gercheva L, Stojanovic A, Peytchev D, Tzvetkov N, Griniute R, Oucheva R, Ulmer H, Kwakkelstein M, Rancati F, Gastl G. Petzer AL, et al. Among authors: wolf d. Haematologica. 2010 Jun;95(6):908-13. doi: 10.3324/haematol.2009.013979. Epub 2010 Feb 9. Haematologica. 2010. PMID: 20145273 Free PMC article. Clinical Trial.
2,856 results